#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes Endpoints NewsWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s CNBCBlockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs Scientific AmericanExperimental Lilly combination drug tops Zepbound in weight-loss trial reuters.com‘Godzilla’ of weight-loss drugs could provide other important health benefits The Guardian
